Plain-English translation of NCT05828511 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new experimental medication called in people who have recently been diagnosed with multiple myeloma and have not yet received any treatment. The medication is designed to work by activating your immune system to attack myeloma cells. Researchers want to find out if this treatment is safe, how well it works, and what the best dose is.
Multiple myeloma is a serious blood cancer that currently requires several different types of treatment. This study exists to find out whether this new immune-boosting medication could become a new option for patients when they are first diagnosed, potentially offering a different approach to fighting the disease.
You likely qualify if…
You likely don't qualify if…
You will receive doses of the experimental medication starting at lower amounts and increasing over time. Depending on whether your cancer is treatable with a stem cell transplant, you may receive the medication for a set period before transplant, or you may continue receiving it until your disease progresses. You will have regular clinic visits for blood tests, scans, and check-ins to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States